Access through your institution

通过您的机构访问

Buy or subscribe

购买或订阅

In patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity, treatment with the glucagon-like peptide 1 receptor agonist semaglutide (2.4 mg) leads to large reductions in HF-related symptoms and physical limitations, improves exercise function and decreases body weight compared with placebo, according to the STEP-HFpEF trial.

在保留射血分数（HFpEF）和肥胖的心力衰竭（HF）患者中，用胰高血糖素样肽1受体激动剂semaglutide（2.4 根据STEP-HFpEF试验，与安慰剂相比，mg可显著降低HF相关症状和身体局限性，改善运动功能并减轻体重。

The benefits were observed across all obesity categories and the magnitude of improvement in symptoms and physical limitations was directly related to the degree of weight loss..

在所有肥胖类别中观察到益处，症状和身体限制的改善程度与体重减轻程度直接相关。。

This is a preview of subscription content, access via your institution

这是订阅内容的预览，可通过您的机构访问

Access options

访问选项

Access through your institution

通过您的机构访问

Access through your institution

通过您的机构访问

Change institution

变革机构

Buy or subscribe

购买或订阅

Access Nature and 54 other Nature Portfolio journalsGet Nature+, our best-value online-access subscription24,99 € / 30 dayscancel any timeLearn moreSubscription info for Chinese customersWe have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.Go to naturechina.comRent or buy this articlePrices vary by article typefrom$1.95to$39.95Learn morePrices may be subject to local taxes which are calculated during checkout.

Access Nature和54个其他自然投资组合期刊获取Nature+，我们的最佳价值在线访问订阅24,99欧元/30天SCANCEL任何timeLearn更多中国客户订阅信息我们为中国客户提供专门网站。请访问naturechina.com订阅本期刊。去naturechina.comRent或购买本文价格因文章类型而异，从1.95美元到39.95美元不等。了解更多价格可能会受到结帐期间计算的当地税的约束。

Additional access options:

其他访问选项：

Log in

登录

Learn about institutional subscriptions

Read our FAQs

Contact customer support

联系客户支持

ReferencesOriginal articlesKosiborod, M. N. et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2306963 (2023)Article

参考文献原始文章Kosiborod，M。N.等.Semaglutide治疗射血分数和肥胖保留的心力衰竭患者。N、 英格兰。J、 医学。https://doi.org/10.1056/NEJMoa2306963（2023）条

PubMed

PubMed

Google Scholar

谷歌学者

Borlaug, B. A. et al. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat. Med. https://doi.org/10.1038/s41591-023-02526-x (2023)Article

Borlaug，B.A。等人Semaglutide在HFpEF中的肥胖类别和体重减轻：STEP-HFpEF试验的预先指定分析。Nat.Med。https://doi.org/10.1038/s41591-023-02526-x（2023）条

PubMed

PubMed

Google Scholar

谷歌学者

Download referencesAuthor informationAuthors and AffiliationsNature Reviews Cardiology http://www.nature.com/nrcardio/Irene Fernández-RuizAuthorsIrene Fernández-RuizView author publicationsYou can also search for this author in

下载参考文献作者信息作者和附属机构评论心脏病学http://www.nature.com/nrcardio/IreneFernández-RuizauthorsireneFernández-RuizView作者出版物YOU也可以在

PubMed Google ScholarCorresponding authorCorrespondence to

PubMed谷歌学者通讯社

Irene Fernández-Ruiz.Rights and permissionsReprints and PermissionsAbout this articleCite this articleFernández-Ruiz, I. Semaglutide is beneficial in patients with HFpEF and obesity.

IreneFernández-Ruiz。权利和许可本文的印刷和许可引用本文Fernández-Ruiz，I。Semaglutide对HFpEF和肥胖患者有益。

Nat Rev Cardiol (2023). https://doi.org/10.1038/s41569-023-00935-6Download citationPublished: 14 September 2023DOI: https://doi.org/10.1038/s41569-023-00935-6Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard.

Nat Rev Cardiol（2023）。https://doi.org/10.1038/s41569-023-00935-6Download引用发布时间：2023DOI 9月14日：https://doi.org/10.1038/s41569-023-00935-6Share本文任何您共享以下链接的人都可以阅读此内容：获取可共享链接抱歉，本文目前不提供可共享链接。复制到文件夹。

Provided by the Springer Nature SharedIt content-sharing initiative

由Springer Nature SharedIt内容共享计划提供